3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Carcinoma, Medullary
3
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Interventions
Temozolomide
23
Radiotherapy
15
Radiation
7
Bevacizumab
6
temsirolimus
5
Sirolimus
5
Radiotherapy, Conformal
5
Erlotinib Hydrochloride
5
Carmustine
5
Carboplatin
5
Radiotherapy, Intensity-Modulated
4
Everolimus
4
Vorinostat
3
Irinotecan
3
veliparib
2
tipifarnib
2
plerixafor
2
pembrolizumab
2
atezolizumab
2
Surgical Procedures, Operative
2
Sorafenib
2
Gefitinib
2
Fluorodeoxyglucose F18
2
Cilengitide
2
Chemotherapy, Adjuvant
2
vatalanib
1
vandetanib
1
terameprocol
1
tandutinib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gliosarcoma
×
vandetanib
×
Clear all
NCT00441142
2019-03-05
Zactima
Dana-Farber Cancer Institute
Phase 1/2
Completed
119 enrolled
15 charts